
The Biotech Growth Trust PLC
Information as at 31 October 2026

Investment Objective and Benchmark Index

The Biotech Growth Trust PLC (the "Company") seeks capital appreciation through investment in the worldwide biotechnology industry. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (net, total return, sterling adjusted).

Five Years Performance (%)

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed; an investor may receive back less than the original amount invested.



Share Price (total return) +14.6%
Net Asset Value per share (total return) +15.3%
Benchmark: NASDAQ Biotechnology Index (net, total return, sterling adjusted) +51.3%

Source: Morningstar.

Ten Largest Holdings as at 31 October 2026 (% of total investments)

Name	Total
Gilead Sciences	6.8
Amgen	5.6
Vertex Pharmaceuticals	4.3
Biogen	3.8
Regeneron Pharmaceuticals	3.7
Argenx	3.5
Ascendis Pharma	2.9
Vertex Pharmaceuticals	2.7
Cogent Biosciences	2.6
Moderna	2.5
Total	**38.4**





Portfolio Manager
Geoffrey Hsu

Portfolio Manager
Josh Golomb

orbimed

Fast Facts

As at 31 October 2026	
Launch Date	June 1997
AIC Sector	Healthcare & Biotechnology
	Date of Appointment of OrbiMed 19 May 2005
Annual Management Fee (payable by the Company)	*Portfolio Manager:* 0.65% of net assets *Alternative Investment Fund Manager:* 0.30% per annum on the Company's market capitalisation up to £500m, 0.20% on market capitalisation above £500m to £1bn and 0.10% on market capitalisation over £1bn
Performance fee	See Annual Report for details
Ongoing Charges Ratio (OCR) *	1.2%
Continuation Vote	2028 AGM
Year / interim end	31 March / 30 September
Capital Structure	18,304,477 Ordinary Shares of 25p

Trust Characteristics

Number of Holdings	76
Net Assets (£m)	£275.3m
Market Capitalisation (£m)	£252.6m
Dividend Policy	It is not anticipated that the Company will pay a dividend
Gearing (AIC basis)	10.3%
Leverage**	Gross 110.6% Commitment 110.6%
Share Price (p)	1380.00
NAV (p)	1503.82
(Discount) / Premium	(8.2%)
Portfolio Turnover p.a.	215.9%
Active Share***	78.9%

The Biotech Growth Trust PLC
Information as at 31 October 2026

Geographical Breakdown as at 31 October 2026 (%)

North America	84.7%
Continental Europe	11.3%
China	2.2%
United Kingdom	1.1%
Taiwan	0.4%
Unquoted ‡	0.3%
Total	**100.0%**

‡ No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to invest in such private equity funds will be limited to US$15m, after the deduction of proceeds of disposal and other returns of capital. The 0.3% unquoted investments was in Asia.

Source: All portfolio information sourced from Frostrow Capital LLP

Discrete Performance – Calendar Years (%)

Percentage Growth 12 Month Return	2021	2022	2023	2024	2025
NAV	-23.1	-13.6	-7.2	1.2	40.2
Share Price	-24.6	-22.1	-3.5	-4.4	40.4
Index	0.2	-0.3	-1.7	0.7	23.9

Standardised Discrete Performance (%)

	1m	3m	YTD	1yr	3yr	5yr	10yr	Since Manager Appointment 19.05.2005
NAV	-7.4	-11.5	11.8	16.0	89.5	15.3	113.8	1405.3
Share Price	-10.9	-13.9	15.0	16.5	92.2	14.6	109.4	1364.2
Index	1.9	14.2	29.3	34.3	81.6	51.3	151.7	1689.6

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed. An investor may receive back less than the original amount invested.

Source: NAV (total return; fully diluted) & share price (total return) – Morningstar.

**Calculated at the financial year end, includes management fees and all other operating expenses, excludes performance fees.*

***The Board has set the leverage limit for both the Gross and the Commitment basis at 130% of the Company's Net Asset Value.*

****Active Share is expressed as a percentage and shows the extent to which a fund's holdings and their weightings differ from those of the fund's benchmark index. A fund that closely tracks its index might have a low Active Share of less than 20% and be considered passive, while a fund with an Active Share of 60% or higher is generally considered to be actively managed.*


Investment Policy

In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to invest in such private equity funds will be limited to US15m, after the deduction of proceeds of disposal and other returns of capital. The Company's borrowing policy is that borrowings will not exceed 20% of value of the Company's net assets. The Company may be unable to invest directly or efficiently in certain countries or share classes. In these circumstances, the Company may gain exposure by investing indirectly through swaps or other derivative instruments. Exposure to these financial instruments will count towards and be subject to the following limits: Derivative transactions (excluding equity swaps) can be used to mitigate risk and/or enhance return and will be restricted to an aggregate net exposure of 5% of the value of the gross assets measured at the time of the relevant transaction; Equity swaps may be used for efficient portfolio management purposes and aggregate net counterparty exposure through a combination of derivatives and equity swap transactions is restricted to 12% of the value of the gross assets of the Company at the time of the transaction.

The Biotech Growth Trust PLC

Information as at 31 October 2026

Return vs Volatility (Annualised since Date of Appointment of OrbiMed) – Chart (%)



Commentary

In October, the NAV per share was -7.4%, the share price was -10.9% and the benchmark NASDAQ Biotechnology Index (net, total return, sterling adjusted) was +1.9%.

During October, broader equity markets experienced a sharp sell-off in technology stocks and a rotation towards more defensive sectors, including healthcare. Despite generally resilient corporate earnings, investor scrutiny intensified around the significant capital being deployed towards artificial intelligence infrastructure and whether these investments will generate adequate returns.

Within biotechnology, the defensive rotation resulted in strength in the large cap names, with smaller biotechnology companies continuing to face significant selling pressure. Volatility in the 10-year Treasury yield remained high as well, exacerbating this divergence given that small cap stocks are more sensitive to interest rate volatility. The Company's overweighting in small caps and underweighting in large caps resulted in significant underperformance versus the benchmark.

Another factor impacting the Company's performance was a significant reduction in the gross exposure of biotech positions by hedge funds. Morgan Stanley reported that the most crowded biotech longs were being sold and the most crowded biotech shorts were being bought during the month. This degrossing meant that many of the companies we consider high quality that hedge funds held long suffered the largest share price declines, while many of the lower quality companies that had been popular shorts outperformed as funds covered their short positions. Given that the Company held many of these popular longs, this degrossing effect artificially depressed the share prices of many of those names. In light of these developments, the Company took a more defensive posture, reducing small and mid cap names in the portfolio and increasing our exposure to large caps. We continue to believe that as 10-year Treasury yields stabilise, shares of small and mid-cap biotech companies will eventually recover from these transiently depressed levels.

Following the month end, the U.S. midterm elections delivered a sweeping Democratic victory, with Democrats taking decisive control of both chambers of Congress. It is unclear what Democrats will be able to achieve legislatively given that President Trump is likely to veto many of their proposed bills. However, it is possible that there will be some headline noise for the biopharmaceutical industry in 2027 if Democrats propose new policies to lower drug prices in the U.S. We do not expect any meaningful changes to drug pricing in the medium term but will continue to monitor the political situation.

After a two-month hiatus, a couple of meaningful public biotech M&A transactions were announced in October. Viatris acquired Pacira BioSciences for $1.65bn, representing a 45% premium to the stock's last closing price prior to the announcement. The transaction builds Viatris's non-opioid pain portfolio in anticipation of the potential approval of the company's drug meloxicam and gives Viatris access to Pacira's commercialisation team. Merck KGaA also announced the acquisition of Silence Therapeutics for $1.3bn, representing a 130% premium to the company's prior closing price. Merck KGaA secured the rights to divesiran, a short interfering RNA being developed for a rare blood cancer called polycythemia vera, following positive Phase 2 data in August. While neither acquisition target was held in the portfolio, the return of M&A activity is encouraging for the biotech sector more broadly.

Regeneron Pharmaceuticals, Arcutis Biotherapeutics, and Gilead Sciences were the largest positive contributors to performance during the month. Regeneron's stock price surged in October on the heels of a strong 3Q26 earnings update. Arcutis built on September momentum as investor fears about the company's ability to meet 2026 revenue guidance continued to be assuaged by stronger than expected prescription trends for its Zoryve franchise. Shares of Gilead performed well after beating 3Q26 earnings expectations and raising full-year guidance. Regeneron and Gilead also benefited from a macro level shift into large cap biotech.

LongBio Pharma, Pyxis Oncology, and Insilico Medicine were the largest negative contributors to performance during the month. LongBio underperformed due to tightening liquidity in the Hong Kong market and an overreaction to a perceived delay in a licensing deal for its lead drug. Pyxis shares remained under pressure during the month, not unlike other small cap clinical stage biotechs. Insilico Medicine shares fell in line with the broader Chinese stock market.

Codes

Sedol	0038551
ISIN	GB0000385517
Legal Entity Identifier (LEI)	549300Z41EP32MI2DN29
Global Intermediary Identification Number (GIIN)	U1MQ70.99999.SL.826
Bloomberg	BIOG LN
EPIC	BIOG

Discount / Premium Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to NAV per share at which the shares trade to no more than 6%. Shares bought back will be cancelled.

How to Contact Us

Frostrow Capital LLP
25 Southampton Buildings
London, WC2A 1AL

Tel.: 0203 008 4910
Fax: 0203 043 8889

Website: www.frostrow.com
Email: info@frostrow.com

The Biotech Growth Trust PLC

Information as at 31 October 2026

Risk Warnings

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. Shares of the Company are bought and sold on the London Stock Exchange (LSE). The price you pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company. Usually, at any given time, the price you pay for a share will be higher than the price you could sell it. For further information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at www.biotechgt.com. The Company can borrow to purchase investments, this could potentially magnify any losses or gains made by the Company.

Target Market

The Company is suitable for investors seeking an investment that aims to deliver total returns over the longer term (at least five years), is compatible with the needs for retail clients, professional clients and eligible counterparties, and is eligible for all distribution channels. The Company may not be suitable for investors who are concerned about short-term volatility and performance, have low or no risk tolerance or are looking for capital protection, who are seeking a guaranteed or regular income, or a predictable return profile. The Company does not offer capital protection.

Value Assessment

Frostrow Capital LLP has conducted an annual Value Assessment on the Company in line with Financial Conduct Authority ("FCA") rules set out in the Consumer Duty regulation. The Assessment focuses on the nature of the product, including benefits received and its quality, limitations that are part of the product, expected total costs to clients and target market considerations. Within this, the assessment considers quality of services, performance of the Company (against both benchmark and peers), total fees (including management fees and entry and exit fees as applicable to the Company), and also considers whether vulnerable consumers are able to receive fair value from the product.

Frostrow Capital LLP concluded that the Company is providing value based on the above assessment.

Important Information

The Biotech Growth Trust PLC is a public limited company whose shares are listed on the LSE and is registered with HMRC as an investment trust. The Company has an indeterminate life, although shareholders consider and vote on the continuation of the Company at least every five years. The next continuation vote will be held in 2028.

This financial promotion is issued by Frostrow Capital LLP which is authorised and regulated by the FCA.

Disclaimers

Morningstar 2026. All rights reserved. The information, sourced from Morningstar, contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied, adapted or distributed; (3) is not warranted to be accurate, complete or timely; and (4) does not constitute advice of any kind, whether investment, tax, legal or otherwise. User is solely responsible for ensuring that it complies with all laws, regulations and restrictions applicable to it. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information, except where such damages or losses cannot be limited or excluded by law in your jurisdiction. Past performance is no guarantee of future results